Cloned DNA sequences, hybridizable with genomic RNA of lymphadenopathy-associated virus (LAV)

Abstract: The invention relates to cloned DNAs which contains a DNA fragment hybridizable with the genomic RNA of LAV viruses. They are useful as probes for the in vitro detection of viral infection in biological samples taken from persons possibly afflicted with AIDS.

Description: The invention relates to cloned DNA sequences hybridizable to genomic RNA and DNA of lymphadenopathy-associated virus (LAV), a process for their preparation and their uses. It relates more particularly to stable probes including a DNA sequence which can be used for the detection of the LAV virus or related viruses or DNA proviruses in any medium, particularly biological, samples containing of any them. Lymphadenopathy-associated virus (LAV) is a human retrovirus first isolated from the lymph node of a homosexual patient with lymphadenopathy syndrome, frequently a prodrome or a benign form of acquired immune deficiency syndrome (AIDS) (cf. 1). Subsequently other LAV isolates have been recovered from patients with AIDS or pre-AIDS (cf. 2―5). All available data are consistent with the virus being the causative agent of AIDS (cf. 11). The virus is propagated on activated T lymphocytes and has a tropism for the T-cell subset OKT4 (cf. 2―6), in which it induces a cytopathic effect. However, it has been adapted for growth in some Epstein-Barr virus transformed B-cell lines (cf. 7), as well as in the established T-lymphoblastic cell line, CEM. LAV-like viruses have more recently been independently isolated from patients with AIDS and pre-AIDS. These viruses called HTLV-III (Human T-cell Leukemia/Lymphoma virus type III (cf. 12―15) and ARV (AIDS-associated retrovirus) have many characteristics similar to those of LAV and they represent independent isolates of the LAV prototype. For the convenience of language they will hereafter all be referred to as "LAV". Detection methods so far available are based on the recognition of viral proteins. Such a method is disclosed in European Application EP―A―0138667 titled "Antigènes, moyens et méthode pour le diagnostic de lymphadénopathie et du syndrome d'immunodépression acquise" filed on September 14, 1984 under the priority of British Application Serial Nr. 83 24800 filed on September 15, 1983. As a matter of fact a high prevalence of anti-p25 antibodies has been found in the sera of AIDS and pre-AIDS patients and to a lower but significant extent in the high-risk groups for AIDS (cf. 8―10). The conflicting European Application EP―A―0173529 discloses recombinant clones of HTLV-III which are distinct from the ones of the present application. The present invention aims at providing new means which should not only also be useful for the detection of LAV or related viruses (hereafter more generally referred to as "LAV viruses"), but also have more versatility, particularly in detecting specific parts of the genomic DNA of said viruses whose expression products are not always detectable by immunological methods. Reference is hereafter made to the drawings in which: Fig. 1 shows restriction maps of preferred LAV inserts contained in plasmid recombinants; Fig. 2 shows restriction maps of complete LAV fragments; Fig. 3 is a restriction map of a complete LAV genome (clone λJ19); Figs. 4 to 11 show the whole sequence of the LAV genoma, the restriction map of which is shown in Fig. 4. The DNAs according to the invention consist of DNAs which contain DNA fragments, hybridizable with the genomic RNA of LAV. Particularly said DNAs consist of said cDNAs or cDNA fragments or of recombinant DNAs containing said cDNAs or cDNA fragments. Preferred cloned cDNA fragments respectively contain the following restriction sites in the respective orders which follow (from the 3' end to the 5' end): 1) HindIII, SacI, BglII (LAV 75) 2) HindIII, SacI, BglII, BglII, KpnI (LAV 82) 3) HindIII, SacI, BglII, BglII, KpnI, XhoI, BamHI, HindIII, BglII (LAV 13). The LAV 75, LAV 82 and LAV 13 designations correspond to the designations of the recombinant plasmids designated as pLAV 75, pLAV 82 and pLAV 13 respectively, in which they were first cloned. In other words LAV 75, LAV 82 and LAV 13 respectively present as inserts in said recombinant plasmids. For convenience the designations LAV 75, LAV 82 and LAV 13 will be further used throughout this specification to designate the cDNA fragments, whether the latter are in isolated form or in a plasmid form, whereby the other DNA parts of said last mentioned recombinants are identical to or different of the corresponding parts of pLAV 75, pLAV 82 and pLAV 13 respectively. Preferred cDNAs also (like LAV 75, LAV 82 and LAV 13) contain a region corresponding to the R and U 3 regions of the LTR (Long Terminal Repeat) as well as the 3' end of the coding region of the retroviral DNA, particularly if it is assumed that the retroviral structure of LAV is in general agreement with the retroviral genomic structures to date. LAV 13 which has a size of about 2.5 Kbp has been found of particular advantage. It is highly specific of LAV or LAV related viruses and does also recognizes more of the LAV retroviral genomes than do LAV 75 or LAV 82. Particularly LAV 13 enabled the identification of the RU 5 junction of the retroviral genomes within the LTR and, subsequently, the sizes of the LAV genomes, which average from about 9.1 to about 9.2 kb. LAV 13 is free of restriction sites for the following enzymes Eco RI, Nru I, Pvu I, Sal I, Sma I, Sph I, Stu I and Xba I. LAV 13 further appears to contain at least part of the DNA sequences corresponding to those which, in retroviral genomes, code for the envelope protein. The invention further relates to any of the fragments contained in the cDNA which seems to correspond to part of the whole of the LAV retroviral genome, which is characterized by a series of restriction sites in the order hereafter (from the 5' end to the 3' end). The coordinates of the successive sites of a preferred whole LAV genome (restriction map) are indicated hereafter too, with respect to the Hind III site (selected as of coordinate 1) which is the located in the R region. The coordinates are estimated to within ±200 bp. Some coordinates are better established than others. Hind III 0 Sac I 50 Bam HI 460 Hind III 520 Barn HI 600 Pst I 800 Hind III 1 100 Bgl II 1 500 Kpn I 3 500 Kpn I 3 900 Eco RI 4 100 Eco RI 5 300 Sal I 5 500 Kpn I 6 100 Bgl II 6 500 Bgl II 7 600 Hind III 7 850 Bam HI 8 150 Xho I 8 600 Kpn I 8 700 Bgl II 8 750 Bgl II 9 150 Sac I 9 200 Hind III 9 250 The abovesaid DNA according to the invention optionally contains an additional Hind III approximately at the 5 550 coordinate. More particularly the invention pertains to a DNA having an approximate size of 9.1 kb and comprising the series of restriction sites referred to in Fig. 3. The invention further relates to other preferred DNA fragments corresponding substantially to those which in relation to the abovesaid restriction map extend respectively: from approximately Kpn I (6 100) to approximately Bgl II (9 150) said fragment being thought to correspond at least in part to the gene coding for the proteins of the envelope; in particular a protein p110 of about 110,000 Daltons is encoded by this region; from approximately Kpn I (3 500) to approximately Bgl II (6 500), said fragment being thought to correspond at least in part to the pol gene, coding for the virus polymerase; from approximately Pst I (800) to approximately Kpn I (3 500), said fragment being thought to correspond at least in part to the gag gene, which codes for the core antigens, including the p25, the p18, and the p13 proteins. The invention also relates to additional DNA fragments, hybridizable with the genomic RNA of LAV as they will be disclosed hereafter. It further relates to DNA recombinants containing said DNAs or cDNA fragments. More particularly the invention relates to any fragment corresponding to the above ones, having the same sites at same distances from one another, all of these fragments having in common the capability of hybridizing with said LAV retroviral genome. Additional features of the invention will appear in the course of the disclosure of additional features of preferred DNAs of the invention, including restriction maps and nucleotide sequences, the preparation conditions and the properties of which will be illustrated hereafter in a non limitative manner. 1. Construction of a cDNA library 1.1 Virus purification Virions were purified from FR8, an immortalized, permanent LAV producing B-Lymphocyte line (cf. 7) (deposited at the "Collection Nationale de Cultures de Micro-organismes" of the Institut Pasteur of Paris, under Nr. I-303 on May 9, 1984). The purification protocol was described (cf. 1). The main steps were: polyethylene-glycol treatment of culture supernatant, pelleting through 20% sucrose cushion, banding on 20―60% sucrose gradient and pelleting of the virus-containing fractions. 1.2 First strand cDNA synthesis The virus associated detergent activated endogenous reaction is a technique bringing into play the reverse transcriptase of the virus, after purification thereof and lysis of its envelope. For each reaction, purified virus corresponding to 250―300 ml of FR8 supernatant was used. Final reaction volume was 1 ml. Incubation was at 37°C for 45 mn. Protein concentration was about 250 microg/ml. Buffer was: NaCl 25 mM; Tris HCl pH 7.8 50 mM, dithiothreitol 10 mM, MgCl 2 6 mM, each of dATP, dGTP, dTTP at 0.1 mM, Triton® X-100 0.02%; oligo dT primer 50 microg/ml. The cDNA was labelled 15 mn with alpha 32 P-dCTP 400 Ci/mmole to 0.6 microM plus cold dCTP to 4 microM. Afterwards, cold dCTP was added to 25 microM to ensure optimal elongation of the first strand. The reaction was stopped 30 mn after the dCTP chase by adding EDTA to 20 mM, SDS to 0.5%, digesting one hour with proteinase K at 100 microg/ml and phenol-chloroform extraction. cDNA was then purified on G-50 Sephadex® (Pharmacia) and ethanol precipitated. 1.3 2nd Strand synthesis and cloning Purified cDNA-RNA hybrids were treated with DNA polymerase I and RNase H, according to Gubler and Hoffman (cf. 17). Double-stranded cDNA was dC-tailed with terminal transferase and annealed to dG-tailed Pst-digested pBR 327 (cf. 34) a derivative of pBR 322. A cDNA library was obtained by transfection of E. coli C 600 recBC strain. 2. Detection of LAV-specific clones 2.1 Screening of the library 500 recombinant clones were grown on nitrocellulose filters and in situ colony hybridization (cf. 35) was performed with another batch of cDNA made in endogenous virus-associated reaction as decribed (cf. 1.2) and labelled with 32 P. About 10% of the clones could be detected. A major family was obtained by small-scale amplification of these clones and cross-hybridization of their inserts. Among these clones a major family of hybridizing recombinants was identified. Three of these cDNA clones, named pLAV 13, 75 and 82, carrying inserts of 2.5, 0.6 and 0.8 kb respectively were further characterized (Fig. 1). All three inserts have a common restriction pattern at one end, indicating a common priming site. The 50 bp long common Hind III-Pst I fragment was sequenced (Fig. 1) and shown to contain a polyA stretch preceding the cloning dC tail. The clones are thus copies of the 3' end of a polyA-RNA. The LAV 13 specificity was shown by different assays. The specificity of pLAV 13 was determined in a series of filter hybridization experiments using nick-translated pLAV 13 as a probe. Firstly the probe hybridized to purified LAV genomic RNA by dot and Northern blotting (data not shown). pLAV 13 also hybridizes to the genomic RNA of virus concentrated from culture supernatant directly immobilized on filters (dot blot technique). LAV RNA from different sources: normal T-cells, FR8 and other B-cell LAV producing lines, CEM cells and, although less strongly, LAV from the bone marrow culture from a haemophiliac with AIDs (cf. 3) were detected in a similar manner. Uninfected cultures proved negative. This rapid dot blot technique can be adapted with minor modifications to the detection of LAV in serum or other body fluids. Secondly the probe detected DNA in the Southern blots of LAV-infected T-lymphocytes and in the LAV-producing CEM cell line. No hybridization was detected in the DNA of uninfected lymphocytes nor in the DNA from normal liver (data not shown) under the same hybridization conditions. A third characteristic resulted from the possibility of using LAV 13 to identify the whole retroviral genome of the LAV viruses as disclosed hereafter, Particularly characteristic 1.45 kb Hind III fragment which co-migrates with an internal viral fragment in Hind III cleaved pLAV 13 was detected. Bands at 2.3 and 6.7 kb were also detected. As the probe was only 2.5 kb long and as no junction fragments could be detected, it is probable that these extra-bands represent internal fragments arising from a Hind III polymorphism of the LAV genome. Together these data show that pLAV 13 DNA is exogenous to the human genome and detects both RNA and integrated DNA forms derived from LAV infected cells. Thus pLAV 13 is LAV specific. Being oligo-dt primed, pLAV 13 must contain the R and U3 regions of the LTR as well as the 3' end of the coding region, assuming a conventional retroviral genome structure. Cloning of LAV genomic DNA Having found a Hind III site within the R region of the LTR, it was decided to clone the LAV genome by making a partial Hind III digest of proviral DNA from LAV infected cells. It was found that: (a) partial digestion increased the chance of isolating complete clones and (b) Hind III fragments were easily cloned in lambda replacement vectors. The DNA isolated from T-cells of a healthy donor afte r in vitro infection with LAV was partially digested with Hind III and fractionated. A 9±1.5 kb DNA containing fraction was precipitated and ligated into the Hind III arms of lambda-L47.1 (cf. 18). The cloning of LAV genomic DNA was carried out more particularly as follows: cDNA was prepared from LAV infected T cells as described above, then partially digested with Hind III and fractionated on a 5―40% sucrose gradient in 10 mM Tris · Cl pH 8, 10 mM EDTA, 1 M NaCl (SW41 rotor, 16 hours at 40 000 rpm). A single fraction (9±0.5 kb) was precipitated with 20 microg/ml Dextran T40 as carrier and taken up in TE-buffer (10 mM Tris · Cl pH 8, 1 mM EDTA). Lambda-L47.1 Hind III arms were prepared by first ligating the cos sites followed by Hind III digestion and fractionation through a 5―40% sucrose gradient. Fractions containing only the lambda-Hind III arms were pooled, precipitated and taken up in TE-buffer. Ligation of arms to DNA was made at approximately 200 microg DNA/ml using a 3:1 molar excess of arms and 300 units of T4 DNA ligase (Biolabs). In vitro packaging lysates were made according to (38). After in vitro packaging the phage lysate was plated out on NM538 on a C600 recBC strain. Approximately two million plaques were screened by in situ hybridization (cf. 39) using nitrocellulose filters. Hybridization was performed at 68°C in 1×Denhardt solution, 0.5% SDS, 2×SSC, 2 mM EDTA. Probe: 32 P nick-translated LAV insert of pLAV 13 at >10 8 cpm/microg: Filters were washed 2×30 minutes in 0―1 SSC, 0.1% SDS at 68°C, and exposed to Kodak XAR-5 film for 29―40 hours. Seven positive clones were identified and plaque purified on a C 600 rec BC strain. Liquid cultures were grown and the recombinant phages banded in CsCl. Plage DNA was extracted and digested under the appropriate conditions. Seven independent clones were so derived from approximately two million phage plaques after screening in situ with a nick-translated pLAV 13 insert as a probe. Restriction maps of lambda-J19 as well as of a Hind III polymorph lambda-J81 are shown in Fig. 2. Other recombinants lambda-J27, lambda-J31 and lambda-J57 had the same Hind III map as lambda-J19. The mpa of lambda-J81 is identical but for an additional Hind III site at coordinate of approximately 5 550. The restriction maps of Fig. 2 were oriented by hybridizing blots with respect to pLAV 13 DNA. The restriction map of the LAV 13 cDNA clone is also shown in Fig. 2. The restriction sites of lambda-J19 are: B-Bam HI, Bg-Bgl II, H-Hind III, K-Kpn I, P-Pst I, R-Eco RI, S-Sac I, Sa-Sal I and X-Xho I. Underneath the scale is a schema for the general structure of the retroviruses showing the LTR elements U3, R and U5. Only the R/US boundary has been defined and other boundaries are only drawn figuratively. There may be other Bam HI sites in the 5' 0.52 kb Hind III fragment of lambda-J19. They generate fragments that are too small to be detected. Fig. 2 also shows those Hind III fragments of lambda-J19 and lambda-J81 which are detected by pLAV 13 (marked (+)), those which are not detected (―). More particularly lambda-J19 shows four Hind III bands of 6.7, 1.45, 0.6 and 0.52 kb the first two of which correspond to bands in the genomic blot of Hind III restricted DNA. The smallest bands of 0.6 and 0.52 kb were not seen in the genomic blot but the fact that they appear in all the independently derived clones analyzed indicates that they represent internal and not junction fragments, assuming a random integration of LAV proviral DNA. Indeed, the 0.5 kb band hybridizes with pLAV 13 DNA (Fig. 2) through the small Hind III-Pst I fragment of pLAV 13. Thus the 0.5 kb Hind III these fragment of lambda-J19 contains the R-U5 junction within the LTR. It appears that lambda-J81 is a restriction site polymorph of lambda-J19. Lambda-J81 shows five Hind III bands of 4.3, 2.3, 1.45, 0.6 and 0.52 kb. The 2.3 kb band is readily detected in the genomic blot by a pLAV 13 probe, but not the 4.3 kb fragment. That lambda-J81 is a Hind III polymorph and not a recombinant virus is shown by the fact that nick-translated lambda-J19 DNA hybridizes to all five Hind III bands of lambda-J81 under stringent hybridization and washing conditions. Also other restriction sites in lambda-J81 are identical to those of lambda-J19. Sequencing of the LAV-derived cDNA The sequencing and determination of sites of particular interest was carried out on phage recombinant. The whole recombinant phage DNA of clone λJ19 was sonicated according to the protocol of Deininger (1983), Analytical Biochem. 129, 216. The DNA was repaired by a Klenow reaction for 12 hours at 16°C. The DNA was electrophoresed through 0.8% agarose gel and DNA in the size range of 300―600 bp was cut out and electroeluted and precipitated. Resuspended DNA (in 10 mM Tris, pH 8; 0,1 mM EDTA) was ligated into M13mp8 RF DNA (cut by the restriction enzyme Sma I and subsequently alkaline phosphated), using T4 DNA- and RNA-ligases (Maniatis T et al. (1982)―Molecular cloning―Cold Spring Harbor Laboratory). An E. coli strain designated as TG1 was used for further study. This strain has the following genotype: Δlac pro, supE, thi. F'traD36, proAB, lacl q , ZΔM15, r - . This E. coli TGI strain has the peculiarity of enabling recombinants to be recognized easily. The blue colour of the cells transfected with plasmids which did not recombine with a fragment of LAV DNA is not mdified. To the contrary cells transfected by a recobminant plasmid containing a LAV DNA fragment yield white colonies. The technique which was used as disclosed in Gene (1983), 26 , 101. This strain was transformed with the ligation mix using the Hanahan method (Hanahan D (1983) J. Mol. Biol. 166, 557). Cells were plated out on tryptone-agarose plate with IPTG and X-gal in soft agarose. White plaques were either picked and screened or screened directly in situ using nitrocellulose filters. Their DNAs were hybridized with nick-translated DNA inserts of pUC18 Hind III subclones of λJ19. This permitted the isolation of the plasmids or subclones of λ which are identified in the table hereafter. In relation to this table it should also be noted that the designation of each plasmid is followed by the deposition number of a cell culture of E. coli TGI containing the corresponding plasmid at the "Collection Nationale des Cultures de Micro-organismes" (C.N.C.M.) of the Pasteur Institute in Paris, France. A non-transformed TGI cell line was also deposited at the C.N.C.M. under Nr. I-364. All these deposits took place on November 15, 1984. The sizes of the corresponding inserts derived from the LAV genome have also been indicated. Essential features of the recombinant plasmids ―pJ19―1 plasmid (I-365) 0.5 kb Hind III―Sac I―Hind III ―pJ19―17 plasmid (I-367) 0.6 kb Hind III―Pst 1―Hind III ―pJ19―6 plasmid (I-366) 1.5 kb Hind III (5') Bam HI Xho I Kpn I Bgl II Sac I (3') Hind III ―pJ19―13 plasmid (I-368) 6.7 kb Hind III (5') Bgl II Kpn I Kpn I Eco RI Eco RI Sal I Kpn I Bgl II Bgl II Hind III (3') Positively hybridizing M13 phage plates were grown up for 5 hours and the single-stranded DNAs were extracted. M13mp8 subclones of λJ19 DNAs were sequenced according to the dideoxy method and technology devised by Sanger et al (Sanger et al (1977), Proc. Natl. Acad. Sci. USA, 74 , 5463 and M13 cloning and sequencing handbook, Amersham (1983). The 17-mer oligonucleotide primer α- 35 SdATP (400 Ci/mmol, Amersham), and 0.5X―5X buffer gradient gels (Biggen M. D. et al (1983), Proc. Natl. Acad. Sci. USA, 50 , 3963) were used. Gels were read and put into the computer under the programs of Staden (Staden R. (1982), Nucl. Acids. Res. 10 , 4731). All the appropriate references and methods can be found in the Amersham M13 cloning and sequencing handbook. The complete sequence of λJ19 is shown in Figs. 5―12. Relationship to other human retroviruses HTLV-I and HTLV-II constitute a pair of C-type transforming retroviruses with a tropism for the T-cell subset, OKT4 (cf. 20). An isolate of HTLV-I has been totally sequenced (cf. 21) and partial sequencing of an HTLV-II has been reported (cf. 22―24). Both genomes (one LTR) were approximately 8.3 kb in length, have a pX region and show extensive sequence homology. They hybridize between themselves under reasonably stringent conditions (40% formamide, 5 XSSC) and even at 60% formamide the pX regions hybridize (cf. 26). Thus a conserved pX region is a hallmark of this class of virus. We have compared cloned LAV DNA and cloned HTLV-II DNA (pMO (cf. 27)) by blot-hybridization and found no cross-hybridization under low stringency conditions of hybridization and washing. For example, Hind III digested lambda-J19, lambda-J27 and lambda-J81 were electrophoresed, blotted and hybridized overnight with 32 P nick-translated pMO (HTLV-II) DNA (having a specific activity greater than 0.5×10 8 cpm/microg) in 20% formamide, 5 XSSC, 1×Denhardts solution, 10% Dextran sulphate, at 37°C. Filters were washed at 37°C (t m . 50) t m . 50 using a 53.1% GC content derived from the HTLV-I sequence (21). The washings were repeated at 50°C and 65°C in 1×SSX, 0.1% SDS. Even when hybridized in 20% formamide, 8×SSC (t m . 50) and washed at 37°C in 2×SSC (t m . 50) no hybridization was detected after two days exposure at ―70°C using an intensifying screen. Thus there is no molecular evidence of a relationship between LAV and the HTLV viruses. In addition, the LAV genome is approximately 9 kb long in contrast to 8.3 kb for the HTLV viruses, Despite their comparable genome sizes LAV and Visna (cf. 29) cloned viral genomes do not cross-hybridize, nor does LAV with a number of human endogenous viral genomes (cf. 30) under non stringent conditions (hybridization-20% formamide, 8 SSC, 37°C; washing―2 SSC, 0.1% SDS, 37°C. The invention also relates more specifically to cloned probes which can be made starting from any DNA fragment according to the invention, thus to recombinant DNAs containing such fragments, particularly any plasmids amplifiable in procaryotic or eucaryotic cells and carrying said fragments. As mentioned earlier a preferred DNA fragment is LAV 13. Using the cloned provirus DNA as a molecular hybridization probe―either by marking with radionucleotides or with fluorescent reagents―LAV virion RNA may be detected directly in the blood, body fluids and blood products (e.g. of the antihemophylic factors such as Factor VIII concentrates) and vaccines, i.e. hepatitis B vaccine. It has already been shown that whole virus can be detected in culture supernatants of LAV producing cells. A suitable method for achieving that detection comprises immobilizing virus onto said a support e.g. nitrocellulose filters, etc., disrupting the virion and hybridizing with labelled (radiolabelled or "cold" fluorescent- or enzyme-labelled) probes. Such an approach has already bean developed for Hepatitis B virus in peripheral blood (according to Scotto J. at al. Hepatology (1983), 3 , 379―384). Probes according to the invention can also be used for rapid screening of genomic DNA derived from the tissue of patients with LAV related symptoms, to see if the proviral DNA or RNA is present in host tissue and other tissues. A method which can be used for such screening comprise the following steps: extraction of DNA from tissue, restriction enzyme cleavage of said DNA, electrophoresis of the fragments and Southern blotting of genomic DNA from tissues, subsequent hybridization with labelled cloned LAV provival DNA. Hybridization in situ can also be used. Lymphatic fluids and tissues and other non-lymphatic tissues of humans, primates and other mammalian species can also be screened to see if other evolutionary related retrovirus exist. The methods referred to hereabove can be used, although hybridization and washings would be done under non stringent conditions. The DNA according to the invention can be used also for achieving the expression of LAV viral antigens for diagnostic purposes as well as for the production of a vaccine against LAV. Of particular advantage in that respect are the DNA fragments coding core (gag region) and for envelope proteins, particularly the DNA fragment extending from Kpn I (6 100) to Bgl II (9 150). The methods which can be used are multifold: a) DNA can be transfected into mammalian cells with appropriate selection markers by a variety of techniques, calcium phosphate precipitation, polyethylene glycol, protoplast-fusion, etc. b) DNA fragments corresponding to genes can be cloned into expression vectors for E. coli , yeast- or mammalian cells and the resultant proteins purified. c) The provival DNA can be "shot-gunned" (fragmented) into procaryotic expression vectors to generate fusion polypeptides. Recombinant producing antigenically competent fusion proteins can be identified by simply screening the recombinants with antibodies against LAV antigens. d) The invention also relates to oligopeptides deduced from the DNA sequence of LAV antigen-genes to produce immunogens and antigens and which can be synthesised chemically. All of the above (a―d) can be used in diagnostics as sources of immunogens or antigens free of viral particles, produced using non-permissive systems, and thus of little or no biohazard risk. The invention further relates to the hosts (procaryotic or eucaryotic cells) which are transformed by vectors containing said DNA fragments. The invention finally refers to the purified genomic mRNA, which can either be extracted as such from the LAV viruses or resynthesized back from the cDNA, particularly to a purified mRNA having a size approximating 9.1 to 9.2 kb, hybridizable to any of the DNA fragments defined hereabove or to parts of said purified mRNA. The invention also relates to parts of said RNA. The nucleotidic structures of this purified RNA or of the parts thereof can indeed be deduced from the nucleotidic sequences of the related cDNAs. It will finally be mentioned that lambda-J19 and lambda-J81 have been deposited at the Collection Nationale des Cultures de Micro-organismes (C.N.C.M.) of the Institut Pasteur of Pasteur (France) under Nr. I-338 and I-339 respectively, on September 11, 1984. The invention finally refers to the genomic DNA, the DNA sequence of which can be determined and used to predict the aminoacid sequences of the viral protein (antigens) and to the RNA probes which can be derived from the cDNA. There follows the bibliography to which references have been made throughout this specification by bracketted numbers. All the publications referred to in this bibliography are incorporated herein by reference. References 1 Barré-Sinoussi, F. et al. Science 220, 868―871 (1983). 2 Montagnier, L. et al. in Human T-cell Leukemia Viruses (eds. R. C. Gallo, M. Essex and L. Gross) p. 363―379 (Cold Spring Harbor, New York, 1984). 3 Vilmer, E. et al. Lancet, ii, 753―757 (1984). 4 Ellrodt, A. et al. Lancet, i, 1383―1385 (1984). 5 Feorino, M. P. et al. Science, 225, 69―72 (1984). 6 Klatzmann, D. et al. Science, 225, 59―63 (1984). 7 Montagnier, L. et al. Science, 885, 63―66 (1984). 8 Brun-Vézinet, F. et al. Lancet, i, 1253―1256 (1984). 9 Kalyanaraman, V. S. et al. Science, 225, 321―323 (1984). 10 Brun-Vézinet, F. et al. Science in Press. 11 Montagnier, L, Barré-Sinoussi, F. and Chermann, J. C. in Prog. Immunodef. Res. Therapy, I, (eds. C. Griscelli and J. Vossen) p. 367―372 (Excerpta Medica, Amsterdam, 12 Popovic, M., Sarngadharan, M. G., Read, E. and Gallo, R. C. Science. 224, 497―500 (1984). 13 Gallo, et al. Science, 224, 500―503 (1984). 14 Schüpbach, J. et al. Science, 224, 503―505 (1984). 15 Sarngadharan, M. G., Popovic, M., Bruch, L., Schüpbach, J. and Gallo, R. C. Science, 224, 506―508 (1984). 16 Levy, J. A. et al. Science, 225, 840―842 (1984). 17 Gubler, U., and Hoffman, B. J. Gene, 25, 263―269 (1983). 18 Loenen, W. A. M. and Brammar, W. J. Gene, 10, 249―259 (1980). 19 Fujiyama, A. et al. Nuc. Acids Res., 11, 4601―4610 (1983). 20 Gallo, R. C. et al. Proc Natl. Acad. Sci. USA, 79, 5680―5683 (1982). 21 Seiki, M., Hattori, S., Hirayama, Y. and Yoshida, M. Proc. Natl. Acad. Sci. USA, 80, 3618―3622 (1983). 22 Haseltine, W. A. et al. Science, 225, 419―421 (1984). 23 Sodroski, J. et al. Science, 225, 421―424 (1984). 24 Shimotohno, K. et al. Proc. Natl. Acad. Sci. USA, in press. 25 Chen, I. S. V., McLaughlin, J., Gasson, J. C., Clark, S. C. and Golde, D. W. Nature, 305, 502―505 (1983). 26 Shaw, G. M. et al. Proc. Natl. Acad. Sci. USA, 81, 4544―4548 (1984). 27 Gelmann, E. P., Franchini, G., Manzari, V., Wong-Staal, F. and Gallo, R. C. Proc. Natl. Acad. Sci. USA, 81, 993―997 (1984). 28 Arya, S. K. et al. Science, 225, 927―930 (1984). 29 Harris, J. D. et al. Virology, 113, 573―583 (1981). 30 Steele, P. E., Rabson, A. B., Bryan, T. and Martin, M. A. Science, 225, 943―947 (1984). 31 Montagnier, L. et al. Ann. Virol. (Institut Pasteur), 135 E, 119―134 (1984). 32 Lenz, J. et al. Nature, 308, 467―470 (1984). 33 Chen, I. S. Y., McLaughlin, J. and Golde, D. W. Nature, 309, 276―279 (1984). 34 Soberon, X., Covarrubias, L. and Bolivar, F. Gene, 9, 287―305 (1980). 35 Grunstein, M. and Hognhess, D. Proc. Natl. Acad. Sci. USA, 72, 3961―3965 (1975). 36 Sanger, F., Nicklen, S. and Coulsen, A. R. Proc. Natl. Acad. Sci. USA, 79, 5463―5476 (1977). 37 Southern, E. M. J. Mol. Biol., 98, 503―517 (1975). 38 Ish-Horowicz, D. and Burke, J. F. Nucl. Acids Res., 9, 2989―2998 (1981). 39 Benton, W. D. and Davis, R. W. Science, 196, 180―182 (1977).

Claims: A cloned DNA which contains a DNA corresponding to the LAV retroviral genome contained in λJ19 (CNCM I-338), said cloned DNA including LTR elements U3, R and U5 of said retroviral genome. The DNA of claim 1 which is a cDNA. A cloned DNA which contains a DNA which consists: either of a 3' terminal fragment of the DNA contained in λJ19 (CNCM I-338) including the R and U3 regions of the 3' LTR, and which has up to 2.5 kb which contains the following restriction sites in the respective orders which follow (from the 3' end to the 5' end): 1) either Hind III, Sac I, Bgl II, 2) or Hind III, Sac I, Bgl II, Bgl II, Kpn I, 3) or Hind III, Sac I, Bgl II, Bgl II, Kpn I, Xho I, Bam HI, Hind III, Bgl II. A cloned DNA fragment whose sequence corresponds to the part of the DNA of λJ19, which extends from approximately Kpn I (6100) to approximately Bam HI (8150) thereof. A cloned DNA fragment whose sequence corresponds to the part of the DNA of λJ19, which extends from approximately Kpn I (3500) to approximately Bgl II (6500) thereof. A cloned DNA fragment whose sequence corresponds to the part of the DNA of λJ19, which extends from approximately Pst I (800) to approximately Kpn I (3500) thereof. A probe for the in vitro detection of LAV which consists of a DNA according to any of claims 1 to 6. A method for the in vitro detection of viral infection due to the LAV viruses which comprises contacting a biological sample originating from a person to be diagnosed for LAV infection and containing RNA in a form suitable for hybridization with the probe of claim 7 under hybridizing conditions and detecting the hybridized probe. A vector, particularly a plasmid, for the transformation of procaryotic or eucaryotic cells which contains an insert consisting of the DNA of any of claims 1 to 6. A microorganism, eucaryotic or procaryotic cell which is transformed by a vector according to claim 9. The purified RNA of LAV virus which has a size from 9.1 to 9.2 kb and which corresponds to the cDNA contained in λJ19 (CNCM I-338).

Inventors: ALIZON MARC, BARRE SINOUSSI FRANCOISE, CHERMANN JEAN-CLAUDE, MONTAGNIER LUC, SONIGO PIERRE, TIOLLAIS PIERRE, WAIN-HOBSON SIMON, ALIZON, MARC, BARRE SINOUSSI, FRANCOISE, CHERMANN, JEAN-CLAUDE, MONTAGNIER, LUC, SONIGO, PIERRE, TIOLLAIS, PIERRE, WAIN-HOBSON, SIMON, Barre Sinoussi, Françoise
Applicants: DE CENTRE NAT, PASTEUR INSTITUT, CENTRE NATIONAL DE, INSTITUT PASTEUR
Application year: 1985
Main classification: C12N15
IPC codes: C07K14, C12R1, A61K39, G01N33, C12N1, C07H21, C12P21, C12N15, C07K16, C12Q1